We are an experienced team with internal drug discovery and development expertise focused on building a pipeline of best-in-class oral drugs for liver and gastrointestinal diseases.
Location: United States, California, San Diego
Employees: 11-50
Total raised: $123M
Founded date: 2014
Investors 9
Funding Rounds 3
| Date | Series | Amount | Investors |
| 10.06.2018 | Series C | $65M | New Enterp... |
| 07.12.2017 | Series B | $22M | - |
| 05.08.2015 | Series A | $36M | - |
Mentions in press and media 17
| Date | Title | Description |
| 14.10.2020 | RayzeBio debuts with $45M to target tumors with radiopharmaceuticals | Radiation, one of the most widely used and effective cancer therapies, is traditionally administered through external beams targeted at the site of a tumor—which Ken Song, M.D., CEO of the newly unveiled company RayzeBio, calls “an incredib... |
| 16.09.2020 | Metacrine, a Rich Heyman biotech targeting NASH and other liver diseases, raises $85M from IPO | A Rich Heyman-backed startup focusing on NASH treatments, as well as other liver, GI and metabolic diseases, is set to start trading Wednesday and join the already-loaded class of 2020 biotech IPOs. Metacrine has raised $85 mil... |
| 11.06.2018 | Term Sheet — Monday, June 11 | ROUND TWO Good morning, Term Sheet readers. Paid Content How can you protect what you can't see? From ExtraHop This marks Eckert’s second round as CEO of Sprout, the Raleigh, N.C.-based developer of a drug intended to treat hypoactive sexua... |
| 10.06.2018 | NEA Joins $65M Series C for Metacrine | SAN DIEGO, June 06, 2018 (GLOBE NEWSWIRE) -- Metacrine, Inc., an innovative biotechnology company developing therapies to benefit patients with liver, gastrointestinal and metabolic diseases, today announced it has completed a Series C fina... |
| 10.06.2018 | Venrock Leads $65M Series C for Metacrine | SAN DIEGO, June 06, 2018 (GLOBE NEWSWIRE) -- Metacrine, Inc., an innovative biotechnology company developing therapies to benefit patients with liver, gastrointestinal and metabolic diseases, today announced it has completed a Series C fina... |
| 08.06.2018 | Metacrine Completes $65M Series C Financing | Metacrine, Inc., a San Diego, CA-based innovative biotechnology company developing therapies to benefit patients with liver, gastrointestinal and metabolic diseases, completed a $65m Series C financing. The round was led by Venrock Healthca... |
| 08.06.2018 | Metacrine Completes $65M Series C Financing | SAN DIEGO, CA, Biotechnology company has completed a Series C financing which raised $65 million. >> Click here for more funding data on Metacrine >> To export Metacrine funding data to PDF and Excel, click here Metacrine... |
| 06.06.2018 | Metacrine raises $65M to kick off NASH clinical testing | Metacrine raised $65 million in a series C round to fund the clinical development of its early stage program in nonalcoholic steatohepatitis and gastrointestinal diseases. Sponsored by Agilent Technologies How would you like to win free ben... |
| 06.06.2018 | Metacrine Completes $65 Million Series C Financing | - |
| 06.06.2018 | Metacrine raises $65M to kick off NASH clinical testing | Metacrine raised $65 million in a series C round to fund the clinical development of its early stage program in nonalcoholic steatohepatitis and gastrointestinal diseases. The San Diego-based biotech’s lead program targets the farnesoid X r... |
Show more